Market Movers

The Cooper Companies, Inc.’s Stock Price Plummets to $85, Experiencing a Sharp 6.57% Decrease

The Cooper Companies, Inc. (COO)

85.00 USD -5.98 (-6.57%) Volume: 5.34M

The Cooper Companies, Inc.’s stock price is currently trading at 85.00 USD, experiencing a significant drop of -6.57% this trading session with a trading volume of 5.34M. The stock’s performance has been turbulent YTD, reflecting a -7.54% decline, indicating a potentially volatile investment opportunity.


Latest developments on The Cooper Companies, Inc.

The Cooper Companies, Inc. recently saw its stock hit a 52-week low at $84.49, but there have been some positive developments leading up to today. The company’s Q1 profit has increased, beating estimates, and they have matched Q1 earnings estimates. Analysts expect that the Q1 earnings will likely reflect seasonal trends. Additionally, there is news of Columbus developer Woda Cooper lining up a second project in Pittsburgh. Despite some mixed results, with Cooper Companies Inc. missing topline expectations, investors are closely watching the company’s performance and stock price movements.


A look at The Cooper Companies, Inc. Smart Scores

FactorScoreMagnitude
Value3
Dividend1
Growth3
Resilience2
Momentum4
OVERALL SMART SCORE2.6

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Cooper Cos has a mixed outlook based on the Smartkarma Smart Scores. While the company scores well in terms of Growth and Momentum, indicating positive trends in these areas, it lags behind in Dividend and Resilience. This suggests that while Cooper Cos may see continued growth and strong market performance, investors may want to consider the company’s ability to weather potential challenges and provide consistent returns through dividends.

Overall, Cooper Cos receives a moderate score on the Smartkarma Smart Scores, with a balanced assessment across key factors. The company’s focus on specialty healthcare products, including contact lenses and surgical instruments, positions it well for long-term success. However, investors should carefully evaluate the company’s performance in each category to determine its potential for sustained growth and profitability in the future.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars